Neurocrine Bio. (NBIX) PT Raised to $125 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Neurocrine Bio. (NBIX) PT Raised to $131 at Baird
August 1, 2018 6:58 AM EDTBaird raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $131.00 (from $122.00) while maintaining an Outperform rating on continued strength in Ingrezza launch.
Analyst Brian Skorney commented, "Neurocrine reported earnings, with net sales of Ingrezza coming in well ahead of expectations at $96.9M.... More
Neurocrine Bio. (NBIX) PT Raised to $135 at Barclays
August 1, 2018 5:38 AM EDTBarclays raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $135.00 (from $100.00) while maintaining a Overweight rating.
... MoreNeurocrine Biosciences (NBIX) Tops Q2 EPS by 10c
July 31, 2018 4:04 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of ($0.07), $0.10 better than the analyst estimate of ($0.17).
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More